Connor, Clark & Lunn Investment Management Ltd. Supernus Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $26 Billion
- Q2 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 122,793 shares of SUPN stock, worth $6.33 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
122,793
Previous 172,259
28.72%
Holding current value
$6.33 Million
Previous $5.64 Million
31.4%
% of portfolio
0.01%
Previous 0.03%
Shares
11 transactions
Others Institutions Holding SUPN
# of Institutions
316Shares Held
61.5MCall Options Held
18.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$536 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$320 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$248 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$156 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.76MShares$142 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.76B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...